Format

Send to

Choose Destination
J Infect Dis. 2009 Mar 1;199(5):711-6. doi: 10.1086/596558.

A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.

Author information

1
Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. rkarron@jhsph.edu

Abstract

Development of live attenuated influenza vaccines (LAIV) against avian strains with pandemic potential is an important public-health strategy. Either 1 or 2 10(7)-TCID(50) doses of H9N2 LAIV A/chicken/Hong Kong/G9/97 were administered intranasally to 50 adults in isolation; 41 participants were H9N2 seronegative, 24 of whom received 2 doses. The vaccine was well tolerated; vaccine shedding was minimal. After 2 doses, 92% of H9-seronegative participants had > or = 4-fold increases in hemagglutination-inhibition antibody, and 79% had > or = 4-fold increases in neutralizing antibody; 100% had responses detected by at least 1 assay. Although replication of the H9N2 LAIV was restricted, 2 doses were immunogenic in H9N2-seronegative adults. Trial registration. ClinicalTrials.gov identifier: NCT00110279 .

PMID:
19210163
PMCID:
PMC2804070
DOI:
10.1086/596558
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center